Byssinosis history and symptoms: Difference between revisions

Jump to navigation Jump to search
Daniel Nethala (talk | contribs)
No edit summary
Anthony Gallo (talk | contribs)
mNo edit summary
 
Line 1: Line 1:
__NOTOC__
{{Byssinosis}}
{{CMG}}
{{CMG}}
{{Byssinosis}}


==Overview==  
==Overview==  
Line 42: Line 43:


[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Disease]]
[[Category:Occupational diseases]]
[[Category:Immunology]]
[[Category:Immunology]]
{{WS}}
{{WH}}

Latest revision as of 14:29, 8 June 2016

Byssinosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Byssinosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Byssinosis history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Byssinosis history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Byssinosis history and symptoms

CDC on Byssinosis history and symptoms

Byssinosis history and symptoms in the news

Blogs on Byssinosis history and symptoms

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Byssinosis history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

According to duration of illness, the clinical presentation of Hypersentivity Pneumonitis is categorized as Acute, Subacute, or Chronic.

History and Symptoms

Symptoms

Acute HP

  • Symptoms develop 4-6 hours following exposure to the inciting agent and then generally resolve spontaneously within 12 hours to several days upon removal of the inciting agent.
  • Symptoms include the abrupt development of

Subacute or Intermittent HP

  • The same symptoms may be present in patients who experience acute attacks on multiple occasions.

Patients with subacute HP present similarly to patients with acute disease, but symptoms are less severe and last longer.

Chronic HP

Patients often lack a history of acute episodes.

They have an insidious onset of cough, progressive dyspnea, fatigue, and weight loss.

Removing exposure results in only partial improvement.

References

Template:WS Template:WH